Literature DB >> 27668936

Determinants of HIV-1 broadly neutralizing antibody induction.

Peter Rusert1, Roger D Kouyos1,2, Claus Kadelka1,2, Hanna Ebner1, Merle Schanz1, Michael Huber1, Dominique L Braun1,2, Nathanael Hozé3, Alexandra Scherrer1,2, Carsten Magnus1, Jacqueline Weber1, Therese Uhr1, Valentina Cippa1, Christian W Thorball4,5, Herbert Kuster1,2, Matthias Cavassini6, Enos Bernasconi7, Matthias Hoffmann8, Alexandra Calmy9, Manuel Battegay10, Andri Rauch11, Sabine Yerly12, Vincent Aubert13, Thomas Klimkait14, Jürg Böni1, Jacques Fellay4,5, Roland R Regoes4, Huldrych F Günthard1,2, Alexandra Trkola1.   

Abstract

Broadly neutralizing antibodies (bnAbs) are a focal component of HIV-1 vaccine design, yet basic aspects of their induction remain poorly understood. Here we report on viral, host and disease factors that steer bnAb evolution using the results of a systematic survey in 4,484 HIV-1-infected individuals that identified 239 bnAb inducers. We show that three parameters that reflect the exposure to antigen-viral load, length of untreated infection and viral diversity-independently drive bnAb evolution. Notably, black participants showed significantly (P = 0.0086-0.038) higher rates of bnAb induction than white participants. Neutralization fingerprint analysis, which was used to delineate plasma specificity, identified strong virus subtype dependencies, with higher frequencies of CD4-binding-site bnAbs in infection with subtype B viruses (P = 0.02) and higher frequencies of V2-glycan-specific bnAbs in infection with non-subtype B viruses (P = 1 × 10-5). Thus, key host, disease and viral determinants, including subtype-specific envelope features that determine bnAb specificity, remain to be unraveled and harnessed for bnAb-based vaccine design.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27668936     DOI: 10.1038/nm.4187

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  57 in total

1.  Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization.

Authors:  Florian Klein; Ron Diskin; Johannes F Scheid; Christian Gaebler; Hugo Mouquet; Ivelin S Georgiev; Marie Pancera; Tongqing Zhou; Reha-Baris Incesu; Brooks Zhongzheng Fu; Priyanthi N P Gnanapragasam; Thiago Y Oliveira; Michael S Seaman; Peter D Kwong; Pamela J Bjorkman; Michel C Nussenzweig
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

Review 2.  Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies.

Authors:  Peter D Kwong; John R Mascola
Journal:  Immunity       Date:  2012-09-21       Impact factor: 31.745

Review 3.  Virological features associated with the development of broadly neutralizing antibodies to HIV-1.

Authors:  Penny L Moore; Carolyn Williamson; Lynn Morris
Journal:  Trends Microbiol       Date:  2015-01-05       Impact factor: 17.079

4.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

5.  Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection.

Authors:  Peter Hraber; Michael S Seaman; Robert T Bailer; John R Mascola; David C Montefiori; Bette T Korber
Journal:  AIDS       Date:  2014-01-14       Impact factor: 4.177

6.  Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses.

Authors:  Michela Locci; Colin Havenar-Daughton; Elise Landais; Jennifer Wu; Mark A Kroenke; Cecilia L Arlehamn; Laura F Su; Rafael Cubas; Mark M Davis; Alessandro Sette; Elias K Haddad; Pascal Poignard; Shane Crotty
Journal:  Immunity       Date:  2013-09-12       Impact factor: 31.745

7.  Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape.

Authors:  Penny L Moore; Elin S Gray; C Kurt Wibmer; Jinal N Bhiman; Molati Nonyane; Daniel J Sheward; Tandile Hermanus; Shringkhala Bajimaya; Nancy L Tumba; Melissa-Rose Abrahams; Bronwen E Lambson; Nthabeleng Ranchobe; Lihua Ping; Nobubelo Ngandu; Quarraisha Abdool Karim; Salim S Abdool Karim; Ronald I Swanstrom; Michael S Seaman; Carolyn Williamson; Lynn Morris
Journal:  Nat Med       Date:  2012-10-21       Impact factor: 53.440

Review 8.  A Blueprint for HIV Vaccine Discovery.

Authors:  Dennis R Burton; Rafi Ahmed; Dan H Barouch; Salvatore T Butera; Shane Crotty; Adam Godzik; Daniel E Kaufmann; M Juliana McElrath; Michel C Nussenzweig; Bali Pulendran; Chris N Scanlan; William R Schief; Guido Silvestri; Hendrik Streeck; Bruce D Walker; Laura M Walker; Andrew B Ward; Ian A Wilson; Richard Wyatt
Journal:  Cell Host Microbe       Date:  2012-10-18       Impact factor: 21.023

9.  Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes.

Authors:  Constantinos Kurt Wibmer; Jinal N Bhiman; Elin S Gray; Nancy Tumba; Salim S Abdool Karim; Carolyn Williamson; Lynn Morris; Penny L Moore
Journal:  PLoS Pathog       Date:  2013-10-31       Impact factor: 6.823

10.  Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies.

Authors:  Jinal N Bhiman; Colin Anthony; Nicole A Doria-Rose; Owen Karimanzira; Chaim A Schramm; Thandeka Khoza; Dale Kitchin; Gordon Botha; Jason Gorman; Nigel J Garrett; Salim S Abdool Karim; Lawrence Shapiro; Carolyn Williamson; Peter D Kwong; John R Mascola; Lynn Morris; Penny L Moore
Journal:  Nat Med       Date:  2015-10-12       Impact factor: 53.440

View more
  74 in total

1.  Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses.

Authors:  Mohammad Mohseni Sajadi; Amir Dashti; Zahra Rikhtegaran Tehrani; William D Tolbert; Michael S Seaman; Xin Ouyang; Neelakshi Gohain; Marzena Pazgier; Dongkyoon Kim; Guy Cavet; Jean Yared; Robert R Redfield; George K Lewis; Anthony L DeVico
Journal:  Cell       Date:  2018-05-03       Impact factor: 41.582

2.  Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time.

Authors:  Karl Stefic; Mélanie Bouvin-Pley; Asma Essat; Clara Visdeloup; Alain Moreau; Cécile Goujard; Marie-Laure Chaix; Martine Braibant; Laurence Meyer; Francis Barin
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

Review 3.  How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design.

Authors:  Marie Pancera; Anita Changela; Peter D Kwong
Journal:  Curr Opin HIV AIDS       Date:  2017-05       Impact factor: 4.283

4.  Identification of a Continuous Neutralizing Epitope within UL128 of Human Cytomegalovirus.

Authors:  Flavia Chiuppesi; Teodora Kaltcheva; Zhuo Meng; Peter A Barry; Don J Diamond; Felix Wussow
Journal:  J Virol       Date:  2017-02-28       Impact factor: 5.103

5.  SIV infection duration largely determines broadening of neutralizing antibody response in macaques.

Authors:  Fan Wu; Ilnour Ourmanov; Andrea Kirmaier; Sivan Leviyang; Celia LaBranche; Jinghe Huang; Sonya Whitted; Kenta Matsuda; David Montefiori; Vanessa M Hirsch
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

Review 6.  The Neutralizing Antibody Response to the HIV-1 Env Protein.

Authors:  Penny L Moore
Journal:  Curr HIV Res       Date:  2018       Impact factor: 1.581

7.  An Immunodominant and Conserved B-Cell Epitope in the Envelope of Simian Foamy Virus Recognized by Humans Infected with Zoonotic Strains from Apes.

Authors:  Caroline Lambert; Damien Batalie; Thomas Montange; Edouard Betsem; Augustin Mouinga-Ondeme; Richard Njouom; Antoine Gessain; Florence Buseyne
Journal:  J Virol       Date:  2019-05-15       Impact factor: 5.103

8.  Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth.

Authors:  Jinghe Huang; Byong H Kang; Elise Ishida; Tongqing Zhou; Trevor Griesman; Zizhang Sheng; Fan Wu; Nicole A Doria-Rose; Baoshan Zhang; Krisha McKee; Sijy O'Dell; Gwo-Yu Chuang; Aliaksandr Druz; Ivelin S Georgiev; Chaim A Schramm; Anqi Zheng; M Gordon Joyce; Mangaiarkarasi Asokan; Amy Ransier; Sam Darko; Stephen A Migueles; Robert T Bailer; Mark K Louder; S Munir Alam; Robert Parks; Garnett Kelsoe; Tarra Von Holle; Barton F Haynes; Daniel C Douek; Vanessa Hirsch; Michael S Seaman; Lawrence Shapiro; John R Mascola; Peter D Kwong; Mark Connors
Journal:  Immunity       Date:  2016-11-15       Impact factor: 31.745

9.  Envelope characteristics in individuals who developed neutralizing antibodies targeting different epitopes in HIV-1 subtype C infection.

Authors:  Bongiwe Ndlovu; Kamini Gounder; Daniel Muema; Nagarajan Raju; Tandile Hermanus; Qiniso Mthethwa; Kim Robertson; Bruce D Walker; Ivelin S Georgiev; Lynn Morris; Penny L Moore; Thumbi Ndung'u
Journal:  Virology       Date:  2020-03-25       Impact factor: 3.616

Review 10.  The antibody response in HIV-1-infected donors.

Authors:  Simone I Richardson; Penny L Moore
Journal:  Curr Opin HIV AIDS       Date:  2019-07       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.